References
- Roschewski M, Dunleavy K, Abramson JS, et al. Multicenter study of Risk-Adapted therapy with Dose-Adjusted EPOCH-R in adults with untreated burkitt lymphoma. J Clin Oncol. 2020;38(22):2519–2529.
- Minard-Colin V, Auperin A, Pillon M, Children’s Oncology Group, et al. Rituximab for High-Risk, mature B-Cell Non-Hodgkin's lymphoma in children. N Engl J Med. 2020;382(23):2207–2219.
- Barnes JA, Lacasce AS, Feng Y, et al. Evaluation of the addition of rituximab to CODOX-M/IVAC for burkitt's lymphoma: a retrospective analysis. Ann Oncol. 2011;22(8):1859–1864.
- Short NJ, Kantarjian HM, Ko H, et al. Outcomes of adults with relapsed or refractory burkitt and high-grade B-cell leukemia/lymphoma. Am J Hematol. 2017;92(6):E114–E117.
- Seitter SJ, McClelland PH, Ahlman MA, et al. Durable remissions in two adult patients with burkitt lymphoma following anti-CD19 CAR T-cell therapy: a single center exeperience. Leuk lymphoma. 2022;:1–5.
- Shah BD, Ghobadi A, Oluwole OO, et al. KTE-X19 for relapsed or refractory adult B-cell acute lymphoblastic leukaemia: phase 2 results of the single-arm, open-label, multicentre ZUMA-3 study. Lancet. 2021;398(10299):491–502.
- Maude SL, Laetsch TW, Buechner J, et al. Tisagenlecleucel in children and young adults with B-Cell lymphoblastic leukemia. N Engl J Med. 2018;378(5):439–448.
- Schuster SJ, Bishop MR, Tam CS, JULIET Investigators, et al. Tisagenlecleucel in adult relapsed or refractory diffuse large B-Cell lymphoma. N Engl J Med. 2019;380(1):45–56.
- Neelapu SS, Locke FL, Bartlett NL, et al. Axicabtagene ciloleucel CAR T-Cell therapy in refractory large B-Cell lymphoma. N Engl J Med. 2017;377(26):2531–2544.
- Abramson JS, Palomba ML, Gordon LI, et al. Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study. Lancet. 2020;396(10254):839–852.
- Wang M, Munoz J, Goy A, et al. KTE-X19 CAR T-Cell therapy in relapsed or refractory Mantle-Cell lymphoma. N Engl J Med. 2020;382(14):1331–1342.